Regulatory MSD secures EC clearance for Keytruda combination therapy for ovarian cancer Pharmaceutical TechnologyMSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer.RegulatoryOncologyRead full story pharminent April 6, 2026 (Last updated: April 6, 2026) Pharmaceutical Technology MSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer. RegulatoryOncologyRead full story Post navigation Previous: Trump revives pharma tariffs with 100% charges, but leaves loopholesNext: Aspect Biosystems receives funding for cellular medicine project Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
